Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer

Nuclear Medicine Communications

Volumn 30, Issue 5, 2009, Pages 362-367

  Das, Tapas ^a   Chakraborty, Sudipta ^a   Sarma, Haladhar D ^a   Venkatesh, Meera ^a   Banerjee, Sharmila ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Holmium 166; Lipiodol; Liver cancer; Oxine

Indexed keywords

8 QUINOLINOL; 8 QUINOLINOL HOLMIUM 166; IODINATED POPPYSEED OIL; LANTHANIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (166)HO OXINE LIPIODOL; (166)HO-OXINE-LIPIODOL; HOLMIUM;

ANIMAL EXPERIMENT; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RETENTION; DRUG SYNTHESIS; DRUG UPTAKE; IMAGE ANALYSIS; ISOTOPE LABELING; LIVER CANCER; NEUTRON RADIATION; NONHUMAN; RAT; SCINTIGRAPHY; TEMPERATURE MEASUREMENT; ANIMAL; DRUG SCREENING; LIVER TUMOR; SYNTHESIS; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HOLMIUM; IODIZED OIL; ISOTOPE LABELING; LIVER NEOPLASMS; OXYQUINOLINE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 67649631832     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328329981a     Document Type: Article

References (26)

1. Parkin MD, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156.
2. Farmer DG, Basuttil RW. The role of multimodal therapy in the treatment of hepatocellular carcinoma. Cancer 1994; 73:2669-2670.
3. Nijsen F, Rook D, Brandt C, Meijer R, Dullens H, Jonnenberg BA, et al. Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. Eur J Nucl Med 2001; 28:743-749.
4. Vente MAD, Hobbelink MGG, van het Schip AD, Zonnenberg BA, Nijsen JFW. Radionuclide liver cancer therapy: from concept to current clinical status. Anticancer Agents Med Chem 2007; 7:441-459.
5. Nijsen JFW, van het Schip AD, Hennink WE, Rook DW, van Rijk PP, de Klerk JMH. Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumors. Curr Med Chem 2002; 9:73-82.
6. Nijsen JFW, Jonnenberg BA, Woittiez JRW, Rook DW, Swildens-van Woudenberg IA, van Rijk PP, et al. Holmium-166 polylactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med 1999; 26:699-704.
7. Anderson JH, Angerson WJ, Willmott N, Kerr DJ, McArdle CS, Cooke TG. Regional delivery of microspheres to liver metastases: the effect of particle size and concentration on intrahepatic distribution. Br J Cancer 1991; 64:1031-1034.
8. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. Eur J Nucl Med Mol Imaging 2006; 33:344-352.
9. Wang SJ, Lin WY, Chen MN, Shen LH, Tsai ZT, Ting G. Preparation and biodistribution of yttrium-90 lipiodol in rats following hepatic arterial injection. Eur J Nucl Med 1995; 22:233-236.
10. Ackerman NB, Lien WM, Kondi ES, Silverman NA. The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to 'small' and 'large' tumours. Surgery 1969; 66:1067-1072.
11. 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization of liver cancer: preliminary study in a rabbit liver cancer model. J Nucl Med 2003; 44:2033-2038.
12. 90Y-oxine-ethiodol, potential radiopharmaceutical for the treatment of liver cancer. Appl Radiat Isot 2003; 58:567-573.
13. 166Ho-labeled hydroxyapatite particles: a possible agent for liver cancer therapy. Cancer Biother Radiopharm 2009; (in press).
14. 166Ho labeled DOTA for possible use in intravascular radiation therapy (IVRT). J Label Compd Radiopharm 2003; 46:197-209.
15. 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001; 28:197-204.
16. Leung WT, Lau WY, Ho S, Chan M, Leung N, Lin J, et al. Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994; 35:1313-1318.
17. Becker S, Laffont S, Vitry F, Rolland Y, Lecloirec J, Boucher E, et al. Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled lipiodol. Nucl Med Commun 2008; 29:815-825.
18. 131I-labeled lipiodol after resection of hepatocellular carcinoma: Progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med 2008; 49:362-366.
19. 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs. Eur J Nucl Med Mol Imaging 2004; 31:542-546.
20. Lambert B, van deWiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2005; 32:980-989.
21. Ehrhardt GJ, Day DE. Therapeutic use of Y-90 microsphere. Int J Radiat Appl Instrum Part B Nucl Med Biol 1987; 14:233-242.
22. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WB, Shapiro B. Hepatic radioembolisation with yttrium-90 containing glass microspheres: preliminary results and clinical follow up. J Nucl Med 1994; 35:1637-1644.
23. Draye M, Thomas S, Cote G, Favre-reguillon C, LeBuzit G, Guy A, et al. Cloud point extraction for selective removal of Gd(III) and Ln(III) with 8-hydroxyquinoline. Sep Sci Technol 2005; 40:611-622.
24. 166Ho]Holmium labelled ethylene dicysteine. Nucl Med Biol 2001; 28:309-317.
25. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Jthakissos DS, Avagoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001; 221:143-152.
26. 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis. Radiochim Acta 2008; 96:55-61.